Are results from immunotherapy in lung cancer durable?

A newly released study shows that Durvalumab (Imfinzi) significantly improved progression-free survival when used as a sequential treatment in patients with locally-advanced, unresectable non–small cell lung cancer (NSCLC) who had not progressed following standard care with platinum-based chemotherapy and radiotherapy.

“These are highly encouraging results for patients with locally-advanced lung cancer for whom surgery is not an option. We look forward to working with regulatory authorities around the world to bring Imfinzi to lung cancer patients as soon as possible.” Sean Bohen, MD, PhD, executive vice president, global medicines development, and chief medical officer at AstraZeneca.